Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelos D Gritzapis

Showing results (1-10 of 47) with videos related to

Pageof 5
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|September 10, 2003
In vivo antitumor activity of NKT cells activated by the combination of IL-12 and IL-18Constantin N Baxevanis, Angelos D Gritzapis, Michael Papamichail
Cancer Immunology, Immunotherapy : CII|September 20, 2011
Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant miceAngelos D Gritzapis, Ioannis F Voutsas, Constantin N Baxevanis
Cancers|May 27, 2026
Intratumor Heterogeneity: A Central Challenge in Modern OncologyConstantin N Baxevanis, Ourania E Tsitsilonis, Angelos D Gritzapis
Cancers|December 23, 2022
Combination Immunotherapy in Prostate CancerConstantin N Baxevanis, Maria Goulielmaki, Angelos D Gritzapis, et al.
Cancer Immunology, Immunotherapy : CII|December 20, 2003
Natural killer lymphocytes: biology, development, and functionMichael Papamichail, Sonia A Perez, Angelos D Gritzapis, et al.
Cancer Immunology, Immunotherapy : CII|May 28, 2004
Generation of human tumor-specific CTLs in HLA-A2.1-transgenic mice using unfractionated peptides from eluates of human primary breast and ovarian tumorsAngelos D Gritzapis, Nectaria N Sotiriadou, Michael Papamichail, et al.
Cancers|December 11, 2025
Exploring the Pivotal Functions of Tertiary Lymphoid Structures in Cancer Prognosis and Immunotherapy OutcomesConstantin N Baxevanis, Michael Sofopoulos, Ourania E Tsitsilonis, et al.
Investigational New Drugs|September 8, 2010
Combined treatment with bevacizumab and standard chemotherapy restores abnormal immune parameters in advanced colorectal cancer patientsNikolaos Tsavaris, Ioannis F Voutsas, Christos Kosmas, et al.
Cancer Research|March 18, 2010
Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cellsAngelos D Gritzapis, Ioannis F Voutsas, Eftychia Lekka, et al.
Stem Cells (Dayton, Ohio)|August 16, 2005
Interactions between human mesenchymal stem cells and natural killer cellsPanagiota A Sotiropoulou, Sonia A Perez, Angelos D Gritzapis, et al.
Pageof 5

Showing results (1-10 of 47) with videos related to

Sort By:
Pageof 5
Journal of Immunology (Baltimore, Md. : 1950)|September 10, 2003
In vivo antitumor activity of NKT cells activated by the combination of IL-12 and IL-18Constantin N Baxevanis, Angelos D Gritzapis, Michael Papamichail
Cancer Immunology, Immunotherapy : CII|September 20, 2011
Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant miceAngelos D Gritzapis, Ioannis F Voutsas, Constantin N Baxevanis
Cancers|May 27, 2026
Intratumor Heterogeneity: A Central Challenge in Modern OncologyConstantin N Baxevanis, Ourania E Tsitsilonis, Angelos D Gritzapis
Cancers|December 23, 2022
Combination Immunotherapy in Prostate CancerConstantin N Baxevanis, Maria Goulielmaki, Angelos D Gritzapis, et al.
Cancer Immunology, Immunotherapy : CII|December 20, 2003
Natural killer lymphocytes: biology, development, and functionMichael Papamichail, Sonia A Perez, Angelos D Gritzapis, et al.
Cancer Immunology, Immunotherapy : CII|May 28, 2004
Generation of human tumor-specific CTLs in HLA-A2.1-transgenic mice using unfractionated peptides from eluates of human primary breast and ovarian tumorsAngelos D Gritzapis, Nectaria N Sotiriadou, Michael Papamichail, et al.
Cancers|December 11, 2025
Exploring the Pivotal Functions of Tertiary Lymphoid Structures in Cancer Prognosis and Immunotherapy OutcomesConstantin N Baxevanis, Michael Sofopoulos, Ourania E Tsitsilonis, et al.
Investigational New Drugs|September 8, 2010
Combined treatment with bevacizumab and standard chemotherapy restores abnormal immune parameters in advanced colorectal cancer patientsNikolaos Tsavaris, Ioannis F Voutsas, Christos Kosmas, et al.
Cancer Research|March 18, 2010
Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cellsAngelos D Gritzapis, Ioannis F Voutsas, Eftychia Lekka, et al.
Stem Cells (Dayton, Ohio)|August 16, 2005
Interactions between human mesenchymal stem cells and natural killer cellsPanagiota A Sotiropoulou, Sonia A Perez, Angelos D Gritzapis, et al.
Pageof 5